ABSTRACT
Tumor necrosis factor alpha (TNF alpha) a pro-inflammatory cytokine is an endogenous mediator of septic shock, inflammation, anti-viral responses and apoptotic cell death. TNF alpha elicits its complex biological responses through the individual or cooperative action of two TNF receptors of mol. wt 55 kDa (TNF-RI) and mol. wt 75 kDa (TNF-RII). To determine signaling events specific for TNF-RII we fused the extracellular domain of the mouse CD4 antigen to the intracellular domain of TNF-RII. Crosslinking of the chimeric receptor using anti-CD4 antibodies initiates exclusively TNF-RII-mediated signals. Our findings show that: (i) TNF-RII is able to activate two members of the MAP kinase family: extracellular regulated kinase (ERK) and c-jun N-terminal kinase (JNK); (ii) TRAF2, a molecule that binds TNF-RII and associates indirectly with TNF-RI, is sufficient to activate JNK upon overexpression; (iii) dominant-negative TRAF2 blocks TNF alpha-mediated JNK activation and (iv) TRAF2 signals the activation of JNK and NF-kappaB through different pathways. Our findings suggest that TNF alpha-mediated JNK activation in fibroblasts is independent of the cell death pathway and that TRAF2 occupies a key role in TNF receptor signaling to JNK.
Subject(s)
Antigens, CD/metabolism , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Mitogen-Activated Protein Kinases , Proteins/metabolism , Receptors, Tumor Necrosis Factor/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Animals , Blotting, Western , CD4 Antigens/genetics , CHO Cells , COS Cells , Cell Death , Cricetinae , Enzyme Activation , Flow Cytometry , Gene Expression , Humans , JNK Mitogen-Activated Protein Kinases , Mice , Mitogen-Activated Protein Kinase 1 , NF-kappa B/metabolism , Receptors, Tumor Necrosis Factor, Type II , Recombinant Fusion Proteins/metabolism , Signal Transduction , TNF Receptor-Associated Factor 2 , Transfection/genetics , Tumor Necrosis Factor-alpha/metabolismABSTRACT
Using a plasmid (pSWS) similar to one that has been successfully used for large-scale production of hepatitis B virus (HBV) envelope protein particles (pSVS) but containing the corresponding woodchuck hepatitis virus (WHV) envelope gene sequences, we have stably transformed the rodent dihydrofolate reductase-deficient cell line CHO dhfr-. Although production of WHV envelope particles in CHO/pSWS cell lines was low, it was sufficient to test whether these particles could bind to polymerized serum albumin. Whereas binding of HBV particles produced in CHO/pSVS cells to polymerized human serum albumin could readily be detected, we found no evidence that the WHV envelope protein particles produced in vitro bind to either human or woodchuck polymerized serum albumin.
Subject(s)
Antigens, Viral/metabolism , Hepatitis B Virus, Woodchuck/immunology , Serum Albumin/metabolism , Viral Envelope Proteins/metabolism , Animals , Antigens, Viral/genetics , CHO Cells , Cell Line , Cricetinae , Recombinant Proteins/metabolism , Serum Albumin, Human , Species Specificity , Transformation, Genetic , Viral Envelope Proteins/geneticsABSTRACT
The FLT3 gene encodes a subclass-III receptor tyrosine kinase (RTKIII). We have determined the structural organization of the downstream part of the human FLT3 gene (also designated dsp-FLT3) that corresponds to the intracellular region of the protein. The coding region is spread over twelve exons spanning 10 kb of genomic DNA. Exon sizes range from 83 to 154 bp, while intron sizes range from 86 bp to more than 1.9 kb. Comparison with the corresponding domain of other RTKIII genes (KIT and FMS) shows that these genes share the same number of exons, which are highly conserved in size, sequence and exon/intron boundary positions. In addition, the intron phase of equivalent introns of FLT3, KIT and FMS are all identical. Our results reinforce our hypothesis based initially only on the KIT and FMS comparison showing that RTKIII genes share a common structural organization and have evolved from a common ancestor gene by cis and trans duplication. Comparison of the genomic organization of the intracellular-encoding part of RTKIII genes with that of RTKI, II and IV genes shows that subclasses III and IV are the most closely related.
Subject(s)
Exons/genetics , Introns/genetics , Proto-Oncogene Proteins/genetics , Receptor Protein-Tyrosine Kinases/classification , Receptor Protein-Tyrosine Kinases/genetics , Base Sequence , Conserved Sequence , Genome, Human , Humans , Molecular Sequence Data , fms-Like Tyrosine Kinase 3ABSTRACT
The high oncogenic efficiency of woodchuck hepatitis virus (WHV) has been correlated with the ability of this virus to provoke insertional activation of myc family genes. To assess the impact of viral integration on liver cell transformation, we have generated transgenic mice carrying the mutated c-myc gene and adjacent viral DNA from a woodchuck tumor, in original configuration. Virtually all mice from two different strains developed hepatocellular carcinoma with a mean latency period of 8-12 months. The c-myc transgene was expressed transiently in neonatal livers, and re-expressed at preneoplastic and neoplastic stages in adult livers. Woodchuck c-myc mRNA driven by the normal P1 and P2 promoters and WHV-specific transcripts encoding viral surface antigens were produced in a strictly co-regulated fashion during development and tumorigenesis, indicating a predominant regulatory influence of the viral enhancer. Furthermore, the activity of the viral enhancer in response to various biological stimuli was apparently modulated by glucose uptake and glucagon/insulin balance in differentiated hepatocytes. In this model, a viral integration event selected from a naturally occurring tumor proved to be determinant for induction of hepatocarcinogenesis, although enforced, liver-specific expression of c-myc was limited to a particular developmental stage.
Subject(s)
Cell Transformation, Neoplastic/genetics , Genes, myc , Hepatitis B Virus, Woodchuck/genetics , Liver Neoplasms, Experimental/genetics , Liver/metabolism , Virus Integration , Animals , Diet , Gene Expression Regulation , Hormones/physiology , Mice , Mice, Transgenic , Mutagenesis, Insertional , RNA, Messenger/genetics , RNA, Messenger/metabolism , Viral Matrix Proteins/geneticsABSTRACT
We have cloned and expressed in Escherichia coli three different parts of the HBx open reading frame, the N- and C-termini and the interior or central portion, using two vector systems. The sera of 43 hepatitis B virus patients representing three clinical categories--asymptomatic carriers, chronic active hepatitis, and hepatitis B patients with cirrhosis--known to be anti-HBx positive, were tested for reactivity against these constructs by Western blotting. The great majority of sera, regardless of the clinical categories, clearly recognise all three parts of HBx, strongly suggesting that the normal mechanism of biosynthesis of the HBx gene product is a straight-forward translation of the open reading frame starting from the first ATG. However, asymptomatic carriers show a marked, often almost exclusive, preference for recognition of the central portion of HBx, while patients with chronic hepatitis and patients with cirrhosis generally recognise all three parts of HBx to a similar extent.
Subject(s)
Carrier State/diagnosis , Hepatitis B/genetics , Trans-Activators/genetics , Amino Acid Sequence , Base Composition , Base Sequence , Blotting, Western , Cloning, Molecular , DNA Polymerase I/blood , Escherichia coli/genetics , Genes, Viral , Hepatitis B/complications , Hepatitis B Antigens/chemistry , Hepatitis B Antigens/genetics , Hepatitis, Chronic/complications , Hepatitis, Chronic/genetics , Humans , Liver Cirrhosis/complications , Liver Cirrhosis/genetics , Liver Cirrhosis/microbiology , Open Reading Frames , Protein Conformation , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Trans-Activators/biosynthesis , Trans-Activators/chemistry , Viral Regulatory and Accessory ProteinsABSTRACT
Polyclonal antibodies directed against the preS2 and S domains of the woodchuck hepatitis virus (WHV) envelope proteins were prepared using synthetic peptides and fusion polypeptides as immunogens. They were tested by immunoblotting and immunoprecipitation of infected woodchuck sera and lysates of a eukaryotic cell line expressing WHV envelope proteins. Only one anti-peptide serum directed against the preS2 domain was reactive with WHV envelope proteins, recognizing the preS2 and preS1 proteins by their preS2 epitopes. With recombinant fusion proteins we generated several anti-S sera, which recognized all envelope proteins, and anti-preS2 antisera, which recognized the preS proteins. Results obtained with our antisera showed that sera of infected woodchucks lack the low glycosylated form (GP33) of the preS2 protein, unlike human hepatitis B virus.
Subject(s)
Antibodies, Viral/immunology , Hepadnaviridae/immunology , Hepatitis, Viral, Animal/immunology , Marmota , Protein Precursors/immunology , Viral Envelope Proteins/immunology , Animals , Glycosylation , Hepatitis, Viral, Animal/microbiology , Immunoblotting , Precipitin Tests , Protein Precursors/blood , Viral Envelope Proteins/bloodABSTRACT
To clarify the significance of the X gene of hepatitis B virus, we have tested for anti-HBx in the serum and HBxAg in the liver at different stages of the natural history of hepatitis B virus infection. Sera were screened by enzyme-linked immunosorbent assay and positive results confirmed by immunoblot. Purified recombinant MS2 Pol-HBx fusion protein was used as target for both assays. Among serial sera of patients with nonfulminant acute hepatitis, 24 of 64 patients (37.5%) were positive for anti-HBx. In fulminant cases, 15 of 36 patients (42%) had anti-HBx. In chronic hepatitis patients with high rates of hepatitis B virus replication, we found a significantly (p less than 0.01) higher prevalence of anti-HBx, 14 of 25 patients (56%), than in those with low replication, 14 of 66 patients (21%), or among asymptomatic HBsAg carrier blood donors (20 of 126 = 16%) without detectable hepatitis B virus replication (p less than 0.0001). The highest prevalence of anti-HBx was found in HBsAg carriers with cirrhosis (41 of 54 patients = 76%) and/or with hepatocellular carcinoma (18 of 33 patients = 54%). The findings suggest that anti-HBx appears as a common and early marker of hepatitis B virus infection, transient in self-limited hepatitis but persisting with progression to chronicity. In chronic hepatitis, the prevalence of anti-HBx correlated with the intensity and duration of hepatitis B virus replication but neither with the severity of the liver disease nor with malignant transformation per se.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Hepatitis B Antibodies/blood , Hepatitis B Antigens/analysis , Hepatitis B virus/immunology , Hepatitis B/immunology , Liver/immunology , Trans-Activators/analysis , Acute Disease , Blotting, Western , Chronic Disease , Enzyme-Linked Immunosorbent Assay , Hepatitis B Antigens/immunology , Hepatitis B virus/genetics , Hepatitis B virus/physiology , Histocytochemistry , Humans , Immunoenzyme Techniques , Predictive Value of Tests , Trans-Activators/immunology , Viral Regulatory and Accessory Proteins , Virus ReplicationABSTRACT
The human proto-oncogene c-fms [FMS] on chromosome 5q33.3 encodes a transmembrane glycoprotein with tyrosine kinase activity that functions as the cell surface receptor for the macrophage colony stimulating factor (CSF-1 or M-CSF). Overlapping bacteriophage clones that included 35 kb of the FMS locus and contained the complete coding sequence of the CSF-1 receptor were subjected to nucleotide sequencing analysis. Comparison with the cDNA sequence of the human c-fms gene indicated that at least one 5' noncoding exon is located far upstream (ca. 26 kb) from sequences encoding the CSF-1 receptor. The FMS coding sequence consists of 21 small exons and heterogeneously sized introns, ranging from 6.3 kb to less than 0.1 kb in complexity.